Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.1059
Abstract: Importance Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear. Objective To determine whether adding denosumab to… read more here.
Keywords: denosumab; trial; nab paclitaxel; randomized clinical ... See more keywords
Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.3850
Abstract: In the absence of an intervening antiresorptive agent, cyclic administration of teriparatide does not increase bone mineral density (BMD) more than standard daily therapy. Because denosumab is a potent antiresorptive agent with a rapid off‐effect,… read more here.
Keywords: bone mineral; cyclic teriparatide; denosumab; osteoporosis randomized ... See more keywords
Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2‐Year Randomized Study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4305
Abstract: Increased bone turnover and rapid bone loss follow discontinuation of denosumab. We investigated the long‐term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab. In this randomized, open‐label, interventional study,… read more here.
Keywords: year; denosumab; group; bone ... See more keywords
Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4551
Abstract: In a randomized clinical trial in patients initiating glucocorticoid therapy (GC‐I) or on long‐term therapy (GC‐C), denosumab every 6 months increased spine and hip bone mineral density at 12 and 24 months significantly more than… read more here.
Keywords: patients initiating; denosumab; denosumab compared; bone ... See more keywords
Denosumab‐Related Osteonecrosis of the Jaw May Not Be a Subject of Teriparatide Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4625
Abstract: We interest the recent article by Everts-Graber and colleagues regarding the higher risk of osteonecrosis of the jaw (ONJ) under denosumab compared to bisphosphonates (BPs) in patients with osteoporosis. (1) It was also reported that… read more here.
Keywords: denosumab; denosumab related; bone; teriparatide treatment ... See more keywords
Denosumab for Prevention of Acute Onset Immobilization‐Induced Alterations of Bone Turnover: A Randomized Controlled Trial
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4694
Abstract: Metabolic bone disease is a devastating condition in critically ill patients admitted to an intensive care unit (ICU). We investigated the effects of early administration of the antiresorptive drug denosumab on bone metabolism in previously… read more here.
Keywords: immobilization; denosumab; bone; serum levels ... See more keywords
Medication‐Related Osteonecrosis of the Jaw in Cancer Patients: Result from the OneFlorida Clinical Research Consortium
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4708
Abstract: Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but severely debilitating drug‐induced bone disorder in the jawbone region. The first MRONJ was reported in 2003 after bisphosphonate (BP) exposure. Recently, other drugs, such as… read more here.
Keywords: denosumab; cancer patients; bps denosumab; consortium ... See more keywords
Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population‐Based Cohort Study
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4804
Abstract: Denosumab can be used in patients with chronic kidney disease (CKD) but has been linked with cases of severe hypocalcemia. The incidence of and risk factors for hypocalcemia after denosumab use are not well established.… read more here.
Keywords: denosumab; kidney; risk; hypocalcemia ... See more keywords
Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan
Sign Up to like & getrecommendations! Published in 2017 at "Osteoporosis International"
DOI: 10.1007/s00198-017-3940-4
Abstract: SummaryWe constructed a Markov microsimulation model among hypothetical cohorts of community-dwelling elderly osteoporotic Japanese women without prior hip or vertebral fractures over a lifetime horizon. Compared with weekly oral alendronate for 5 years, denosumab every 6 months… read more here.
Keywords: alendronate; denosumab; elderly osteoporotic; cost effectiveness ... See more keywords
Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
Sign Up to like & getrecommendations! Published in 2017 at "Osteoporosis International"
DOI: 10.1007/s00198-017-4108-y
Abstract: To the editor, Cases have recently been published about reboundassociated vertebral fractures (RAVFs) after discontinuation of denosumab in patients with postmenopausal osteoporosis [1]. Denosumab therapy lasted between 6 and 42 months, and clinical spontaneous fractures… read more here.
Keywords: switching denosumab; denosumab; discontinuation denosumab; vertebral fractures ... See more keywords
Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis
Sign Up to like & getrecommendations! Published in 2017 at "Osteoporosis International"
DOI: 10.1007/s00198-017-4140-y
Abstract: SummaryTrabecular bone score (TBS) assesses bone quality in the lumbar spine using dual-energy X-ray absorptiometry (DXA) scans. In postmenopausal women with osteoporosis, denosumab significantly improved TBS independently of bone mineral density (BMD). This practical technique… read more here.
Keywords: tbs; denosumab; bone score; women osteoporosis ... See more keywords